Atika Capital Management LLC Biomarin Pharmaceutical Inc Transaction History

Atika Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$76.22 - $98.51 $6.48 Million - $8.37 Million	85,000 New	85,000 $8.2 Million
Q4 2022 Feb 13, 2023	BUY	$80.93 - $108.63 $5.97 Million - $8.01 Million	73,739 New	73,739 $7.63 Million
Q2 2020 Aug 13, 2020	BUY	$79.55 - $124.22 $0 - $0	0 New	0 $0
Q1 2020 May 14, 2020	SELL	$71.37 - $96.85 $1.28 Million - $1.74 Million	-18,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $1.16 Million - $1.55 Million	18,000 New	18,000 $1.52 Million
Q2 2019 Aug 12, 2019	SELL	$80.35 - $93.9 $2.77 Million - $3.24 Million	-34,500 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$84.2 - $98.62 $42,100 - $49,310	500 Added 1.47%	34,500 $3.06 Million
Q4 2018 Feb 14, 2019	BUY	$80.14 - $106.07 $2.72 Million - $3.61 Million	34,000 New	34,000 $2.9 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Atika Capital Management LLC with notifications on news.